Related Experiment Video
Updated: Jun 9, 2025
13:47
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
Published on: June 3, 2018
9.3K
Genetically Proxied Antidiabetic Drug Target and Primary Open-Angle Glaucoma: A Mendelian Randomization Study
Kefu Tang1, Wenqiu Wang2, Weiteng Chang3
1Department of Clinical Laboratory, Prenatal Diagnosis Center, Changning Maternity and Infant Health Hospital East China Normal University Shanghai China.
Health Science Reports
|October 25, 2024
Summary
Genetic analysis suggests inhibiting ABCC8 may reduce primary open-angle glaucoma (POAG) risk in Europeans and East Asians. This highlights ABCC8 as a potential therapeutic target for POAG, warranting further investigation into its mechanisms.
Area of Science:
- Genetics and Ophthalmology
- Pharmacogenomics
- Glaucoma Research
Background:
- Observational studies suggest antidiabetic drugs may reduce primary open-angle glaucoma (POAG) risk, but causality is unproven.
- Genetic variation in drug targets can serve as proxies for long-term drug effects.
- Investigating genetic proxies for antidiabetic drug targets offers insights into POAG risk.
Purpose of the Study:
- To evaluate the potential effect of antidiabetic drug targets on POAG risk using Mendelian randomization.
- To assess the impact of ABCC8, PPARG, GLP1R, and SLC5A2 genetic variants on POAG in European and East Asian populations.
Main Methods:
- A two-sample Mendelian randomization study was conducted.
- Genetic variants associated with HbA1c were used as proxies for antidiabetic drug targets.
- POAG genetic summary statistics from large consortia (IGG, GBMI, FinnGen) were analyzed separately for Europeans and East Asians.
Main Results:
- Consistent evidence showed ABCC8 inhibition has a protective effect on POAG risk across datasets.
- Genetically predicted ABCC8 inhibition significantly lowered POAG risk in both Europeans (OR=0.211) and East Asians (OR=0.070).
- The protective association was primarily mediated through intraocular pressure; no significant associations were found for PPARG, SLC5A2, or GLP1R.
Conclusions:
- Genetically proxied ABCC8 inhibition demonstrates a protective effect against POAG in both European and East Asian populations.
- ABCC8 emerges as a promising drug target for POAG.
- Further research into the mechanisms underlying ABCC8's protective effect is recommended.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
397
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
397
01:06Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
01:24Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
161
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
161
01:28Angle Closure Glaucoma: Treatment
441
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
441